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Type 2 Diabetes in a
Chinese Han
Population
T ype 2 diabetes is both a phenotypi-cally and geneotypically heteroge-neous disease. It is caused by
defective insulin secretion and action.
Protein tyrosine phosphatases (PTPases)
play important roles in insulin cascade
signal transduction and have been sug-
gested to be related to insulin resistance
(1,2). PTP-1B, a member of the PTP fam-
ily, is expressed widely in many tissues,
acting as a negative regulator in the insu-
lin receptor signal transduction pathway
(3–5). The PTP-1B gene is located on the
long arm of human chromosome 20, in
the region of q13.1–q13.2, which has
been linked to quantitative trait loci of
obesity and insulin (6,7). A recent study
by Echwald S.M. et al. (8) demonstrated
that a Pro387Leu variation of the PTP-1B
gene, which resulted in the impairment of
the serine phosphorylation of the PTP-1B
peptide (in vitro experiment), was associ-
ated with type 2 diabetes in a Danish Cau-
casian population with a genotype
relative risk of 3.7 (CI 1.2610.93, P 
0.02). Since studies involving the associ-
ation between the genetic variations and
type 2 diabetes are often controversial and
inconsistent in different ethnic popula-
tions, we tested the association between
the Pro387Leu variation of PTP-1B gene
with type 2 diabetes in a Chinese Han
population for the first time.
The Pro387Leu variation of PTP-1B
gene was detected using PCR and restriction
fragment–length polymorphism in 589
subjects chosen from the Han population
living in southern China, including 329
type 2 diabetic patients (men/women 143/
186, age 59.4  9.9 years, BMI 23.9  3.5
kg/m2) and 238 control subjects (men/
women 100/138, age 57.5  8.3 years, BMI
23.8  3.1 kg/m2). The control subjects un-
derwent a 75-g oral glucose tolerance test
and were diagnosed with normal glucose
tolerance (NGT) in accordance with the
1997 American Diabetes Association crite-
ria. The study was approved by the ethnics
committee of our institution. All the sub-
jects gave informed consent.
In our study, only two subjects het-
erozygous for the mutation were found in
the NGT control group, with genotype
and allele frequencies of 0.008 and 0.004,
respectively. We found another two het-
erozygotes in the diabetic patient group;
the genotype and allele frequencies were
0.006 and 0.003, respectively. The differ-
ences did not reach statistical significance
between groups (P  0.05 for both). The
distribution was consistent with Hardy-
Weinberg equilibrium. We then exam-
ined the impacts of the mutation on
metabolic and anthropometric parame-
ters in both groups. Among NGT control
subjects, there were no significant differ-
ences in age, fasting plasma glucose
(FPG), or lipid profile between the two
subgroups with or without the Leu387
mutation (P  0.05), while BMI was sig-
nificantly higher in subjects with the
Leu387 allele (23.74  3.05 vs. 28.55 
2.19 kg/m2, P  0.027). In the diabetic
patient group, no differences were ob-
served in age, BMI, FPG, HbA1c, C-
peptide, or lipid profile (P  0.05). Since
the mutation rate was quite low in the
examined Chinese Han population and at
the same time there were 31 subjects with
a BMI 27 kg/m2 in the subgroup with-
out the Leu387 mutation, the difference
found in BMI between the mutation car-
riers and noncarriers in the control group
was likely attributed to individual vari-
ance rather than the true difference
caused by the presence of the mutation.
In conclusion, our data indicated that
the mutation of Pro387Leu in PTP-1B
gene was present in the Chinese Han pop-
ulation examined, but this variation was
not associated with type 2 diabetes.
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in Both Diabetic and
Nondiabetic Subjects
The Hoorn Study
D iabetic retinopathy has been associ-ated with increased cardiovascularand all-cause mortality risks among
diabetic populations (1). The exact mech-
anism of this association, however, still
remains unclear (1). Recently, we re-
ported (2) that hypertension, dyslipide-
mia, and obesity are associated with
retinopathy in diabetic and nondiabetic
individuals. Conceivably, these associa-
tions with cardiovascular risk factors,
which explain the occurrence of retinop-
athy in a nondiabetic population, may
also explain the association of retinopathy
and mortality. Therefore, the purpose of
this population-based, prospective co-
hort study was to describe the association
of retinopathy with cardiovascular and
all-cause mortality in diabetic and nondi-
abetic individuals. Further investigation
was directed toward the contribution of
cardiovascular risk factors and risk factors
of retinopathy to the association of reti-
nopathy and mortality risk. The study
population consisted of an age-, sex-, and
glucose tolerance–stratified random sam-
ple of the Hoorn Study (n  631), a study
of diabetes and diabetes complications. At
baseline, the years 1989–1990, extensive
physical and ophthalmological examina-
tions were performed (2). Follow-up on
mortality until January 2002 was avail-
able (median duration 10.7 years; range
0.5–12.2). Cox proportional hazards
analyses were conducted to assess mortal-
ity risks and independent contributions
of cardiovascular risk factors to the asso-
ciation of retinopathy with mortality. Ret-
inopathy was detected in 85 (44
nondiabetic and 41 diabetic) subjects
(13.6%), 88% of whom had nonprolifera-
tive retinopathy. During the follow-up
period, 157 (25.1%) participants died, 62
(9.9%) of whom had a cardiovascular
cause of death. The cardiovascular mor-
tality risks for subjects with retinopathy
adjusted for age and sex were 1.75 (0.60–
5.08) and 2.20 (1.03–4.70) in nondia-
betic and diabetic subjects, respectively.
The all-cause mortality risks were 1.43
(0.74 –2.79) and 2.05 (1.23–3.44) in
nondiabetic and diabetic subjects, respec-
tively. After adjustment for diabetes and
diabetes duration, the mortality risks in
diabetic subjects were 1.67 (0.72–3.86)
for cardiovascular mortality and 1.61
(0.92–2.81) for all-cause mortality. BMI,
prior cardiovascular disease, and triglyc-
erides explained smaller portions of the
association in diabetic subjects, whereas
the mortality risk was only lowered by
glycated hemoglobin in nondiabetic sub-
jects. Adjustment for other cardiovascular
risk factors, such as hypertension, smok-
ing, and homocysteine, did not consider-
ably change the estimates. Finally, after
adjustment for all explanatory risk factors
in diabetic and nondiabetic subjects to-
gether, a 1.4-fold (0.7–2.8) higher risk for
cardiovascular mortality and a 1.4-fold
(0.9–2.1) higher risk for all-cause mortal-
ity in subjects with retinopathy remained
unexplained. The contribution of several
cardiovascular risk factors to the in-
creased risk of (cardiovascular) mortality
might suggest shared pathophysiological
mechanisms in microvascular and macro-
vascular disorders. Other mechanisms
that could possibly contribute to the un-
explained 40% increased mortality risk
include inflammation, endothelial dys-
function, or advanced glycation end
products.
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The Adult Treatment Panel (ATP)-IIIguidelines list diabetes as a coronaryheart disease (CHD) risk equivalent
(1). Therefore, the LDL cholesterol goal of
100 mg/dl for patients with diabetes is
equivalent to that of patients with known
CHD (1,2). Hydroxymethylglutaryl-CoA
reductase inhibitor (statin) therapy is rec-
ommended as first-line treatment in
diabetic patients with elevated LDL cho-
lesterol levels (2,3). Despite maximum
statin doses, not all patients are able to
reach this goal. In addition, some patients
experience drug-induced side effects
when statin doses are titrated upwards in
an attempt to reach that goal. In such
cases, lipid-lowering combination ther-
apy may be warranted because doubling
the statin dose has been shown to only
incrementally improve LDL cholesterol
reduction, whereas the use of lipid-
lowering medications with different
mechanisms of action have demonstrated
synergistic effects (4).
Ezetimibe (Zetia; Merck/Schering-
Plough Pharmaceuticals, North Wales,
PA) is the first in a novel class of antihy-
perlipidemic agents called 2-azetidino-
nes, which act as a selective cholesterol
absorption inhibitor. Ezetimibe is indi-
cated for the treatment of primary hyper-
cholesterolemia, alone or in combination
with statin therapy (5). Compared with
placebo, ezetimibe as monotherapy de-
creases LDL cholesterol levels by 16–19%
(6–8). When it is added to statin therapy,
ezetimibe demonstrates a significant 15–
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20% additional mean percent reduction
in LDL cholesterol levels compared with
statin use alone (9 –11). To date, the
safety and efficacy of ezetimibe in a dia-
betic population has not been reported.
The objective of this report was to retro-
spectively determine the effectiveness and
safety of ezetimibe in patients with diabe-
tes at a private endocrinology practice.
The study population consisted of pa-
tients with diabetes who were prescribed
Zetia, had no medication changes be-
tween baseline and follow-up visits, had
fasting values obtained at baseline and fol-
low-up, and received ezetimibe for a min-
imum of 6 weeks. The 23 identified
patients were elderly (63.2  12.4 years
of age), were obese (95.8  24.9 kg), and
had long-standing diabetes (16.3  12.2
years), but had excellent control of glu-
cose levels (HbA1c 6.9  1.1%) and blood
pressure (115.9  9.3 and 69.1  4.1
mmHg for systolic and diastolic, respec-
tively). Of the 23 patients, 2 had type 1
diabetes. At baseline, 74% (17 of 23) of
patients were receiving statin therapy (for
a minimum of 6 months), including 3 pa-
tients who received combination therapy
with micronized fenofibrate, gemfibrozil,
and sustained-release niacin, respec-
tively. Two additional patients were re-
ceiving sustained-release niacin and
micronized fenofibrate monotherapy, re-
spectively. The remaining four patients
received no antilipidemic medication at
baseline.
The average time of follow-up was 83
days. With the addition of ezetimibe,
there was a statistically significant 21%
mean reduction in total cholesterol
(219.6  44.5 to 174.3  39.9 mg/dl;
P  0.001) and a 34% average decrease in
LDL cholesterol levels (129.3  36.2 to
85.9  27.2 mg/dl, P  0.001). There
were no significant changes in triglycer-
ides (P  0.215), HDL cholesterol (P 
0.06), aspartate aminotransferase (P 
0.444), or alanine aminotransferase (P 
0.319) values. Seventy percent of patients
(16 of 23) had an LDL cholesterol level
100 mg/dl.
Ezetimibe represents a safe and effec-
tive treatment for patients with diabetes
who are not at their LDL cholesterol goals.
Clinicians should consider ezetimibe as a
reasonable addition to statin therapy for
diabetic patients unable to tolerate statins
at high doses or for patients who fail to
reach therapeutic end points on maxi-
mum-dose statin therapy.
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W e describe a case of a 28-year-oldwoman who was admitted to ourhospital with severe diabetic ke-
toacidosis. She was known to have had
type 1 diabetes for 10 years. During the
previous 2 days, she had gone to a party,
drank a considerable amount of alcohol,
and did not administer her regular dose of
insulin.
On admission, she was semicomatose
and tachypnoic, her blood pressure was
90/70 mmHg, and her heart rate 80 bpm.
Laboratory tests showed severe metabolic
acidosis (pH 6.92, bicarbonate 2.2
mmol/l, pCO2 1.49 kPa), very high blood
glucose (75 mmol/l), hyponatremia
(104.3 mmol/l), hypochloremia (70
mmol/l), severe hyperkalemia (8.5 mmol/
l), and elevated blood urea (20.3 mmol/l)
and creatinine (317 mol/l). Blood etha-
nol level was 0.2 g/l. Screening for possi-
ble intoxication, including cocaine,
opiates, and amphetamines, was negative.
Electrocardiogram (ECG) showed sinus
rhythm with wide QRS complexes and
diffuse nonspecific ST changes.
The patient was treated with contin-
uous intravenous saline and insulin infu-
sion. After 12 h, her blood glucose
decreased to 17.5 mmol/l (pH 7.23, bicar-
bonate 12.0 mmol/l, potassium 5.12
mmol/l, and sodium 127.8 mmol/l).
Letters
DIABETES CARE, VOLUME 26, NUMBER 10, OCTOBER 2003 2959
Blood urea decreased to 14.6 mmol/l and
creatinine to 154 mol/l. ECG was also
normalized. After 36 h, the patient expe-
rienced transient stabbing chest pain,
which was partially relieved by the
change of body position. Complex ven-
tricular arrhythmias, including short runs
of ventricular tachycardia, were noticed.
Repeat ECG revealed mild ST elevations
in leads II, III, and aVF with negative T-
waves in leads V2–V4. Echocardiography
revealed somewhat depressed left ventric-
ular systolic function (LVEF 45%) with
hypokinesis of the posterior and inferior
walls. Serum troponin I increased to 343
ng/ml (normal value 0.4 ng/ml). On day
3 she was pain free but still had frequent
premature ventricular beats. Troponin
gradually decreased to 178 ng/ml. ECG
showed ST segment normalization with
flattening of T-waves in leads II, III, and
aVF. Repeat echocardiography on day 5
showed reversal of posterior/inferior wall
hypokinesis and normalization of left
ventricular systolic function. The patient
had an uneventful recovery. Coronary an-
giography on day 13 revealed normal cor-
onary arteries with no evidence of
coronary artery disease.
Different electrocardiographic pat-
terns, including acute pseudoinfarction,
have already been described in patients
with ketoacidosis and hyperkalemia
(1,2). None of these patients, however,
had evidence of myocardial necrosis, as
seen in our case. Despite very high levels
of cardiac specific troponin I, echocardi-
ography demonstrated rapid reversibility
of wall motion abnormalities that corre-
sponded to ECG changes. This is in con-
trast to previous observations showing no
compromise but even increased myocar-
dial contractility during diabetic ketoaci-
dosis (3). The mechanism of myocardial
necrosis in our patient is unclear. It might
have been a late consequence of severe
acid-base and electrolyte disturbances
that might have triggered coronary
spasms leading to ischemic myocardial
necrosis. The coincidence of infectious
myocarditis is less likely, but cannot be
excluded.
In conclusion, severe diabetic ketoac-
idosis might be associated with myocar-
dial necrosis of unknown mechanism
leading to transient wall motion abnor-
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A 56-year-old man with brittle type 1diabetes and unaware of the effectsof hypoglycemia was started on a
continuous subcutaneous insulin infu-
sion (CSII) in April 2000. After 12
months, he achieved excellent glycemic
control, and his HbA1c values averaged
6.5%. During this time, however, the pa-
tient required admission to the hospital
on four separate occasions for diabetic
ketoacidosis despite frequent self-
monitored blood glucose (SMBG) (six to
eight times per day) and frequent catheter
insertion site changes. The patient in-
sisted that he administered subcutaneous
injections, as directed, when there was
any question of pump dysfunction. Med-
ical teams noted that the patient devel-
oped diabetic ketoacidosis very rapidly
on several occasions. During one admis-
sion, he reported an SMBG value of 99
mg/dl at 10:00 A.M. Within 95 min, the
patient was brought to the emergency
room with a glucose level of 510 mg/dl
and an anion gap of 35 mmol/l. Because of
the frequent episodes of diabetic ketoaci-
dosis, the patient’s insulin therapy was
switched from CSII to multiple daily in-
sulin injections. However, the patient
preferred CSII therapy for the quality-of-
life benefits provided by the insulin
pump, particularly the greater flexibility
in meal planning, fewer subcutaneous in-
jections, and less frequent hypoglycemic
episodes. To accommodate the patient’s
wishes and prevent diabetic ketoacidosis,
we devised the following treatment strat-
egy. Sixty percent of basal insulin was
provided by a daily injection of glargine
insulin, and his bolus requirements were
provided by the insulin pump. The basal
rate of the pump was programmed for 0.2
units/h to prevent the insulin from crys-
tallizing within the catheter. After 18
months, the patient has experienced no
further episodes of diabetic ketoacidosis
and has maintained acceptable glycemic
control with HbA1c values averaging
7.1%.
With CSII treatment, our patient had
frequent occurrences of diabetic ketoaci-
dosis, which is a morbid and potentially
lethal consequence of the failure to deliver
adequate amounts of insulin. When basal
insulin infusion rates are interrupted in
patients treated with CSII, the subcutane-
ous reserves of short-acting insulin are in-
sufficient to prevent the metabolic
processes that lead to hyperglycemia and
ketogenesis (1). Glargine insulin is an al-
ternative to CSII therapy for mimicking
physiological basal insulin secretion.
Glargine insulin kinetics demonstrate rel-
atively consistent insulin levels for 24 h
after a single subcutaneous injection
(2,3). In our patient, glargine insulin lim-
ited the ketosis and the associated com-
plications that occurred with temporary
infusion interruptions with the CSII. By
combining daily glargine insulin injec-
tions with short-acting insulin boluses
from an insulin pump, our patient had no
episodes of diabetic ketoacidosis and
maintained the lifestyle benefits provided
by the insulin pump.
We must note that ketoacidosis rates
have diminished in patients treated with
CSII. Currently, the rates of diabetic ke-
toacidosis are similar in patients treated
with CSII or multiple daily injections (4).
However, our strategy may benefit some
patients who have recurrent diabetic ke-
toacidosis on insulin pump therapy.
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Successful Treatment
of Insulin Allergy in
a Type 1 Diabetic




A 21-year-old white woman (BMI21.2 kg/m2) was admitted for man-agement of uncontrolled diabetes
with cutaneous allergies to insulin. Past
medical history was marked by several al-
lergies, including coconuts and penicillin
with laryngeal edema.
Type 1 diabetes was diagnosed 4
years previously and treated by three daily
injections of semisynthetic human insulin
(48 units/day). Four months later, the pa-
tient developed a local allergic reaction, a
nettle rash without systemic manifesta-
tion that involved all injection sites. This
reaction began 5 min after each injec-
tion despite H1 antihistamine treatment
and subsided after 3–4 h, suggesting a
type 1 IgE-mediated hypersensitivity re-
action. She had a significant eosinophilia
at 800.106/l (normal 0–500). Prick skin
testing was negative but intradermal tests
with animal or human insulin, NPH or
regular, and protamine were both positive
without dilution. Unfortunately, rapid-
acting analogs of insulin were not tested,
but the patient developed a cutaneous re-
action after a premeal injection of lispro
(Eli Lilly), which is a recombinant analog
of insulin that may be less antigenic be-
cause it does not aggregate to form poly-
mers (1,2). Poor compliance resulted in
intermittent insulin administration and
poor metabolic control. HbA1c was
13.5% (normal 6%) at entry.
Gradual desensitization with low
doses of insulin was not appropriate be-
cause of the subject’s strict insulin re-
quirements. Based on the few literature
reports available (3–5), we initiated a
treatment with continuous subcutaneous
insulin using lispro insulin at a basal rate
of 1.6 units/h. We chose to use an external
insulin pump infusion as a low-dose pro-
vider for both desensitization and treat-
ment of diabetes. Boluses were replaced
with temporarily increased basal rates (2
units/h) over 3 h starting 1 h before meals,
which were based on low– glycemic index
foods (6), to avoid potential allergy reac-
tivation by the necessarily large premeal
doses of insulin. The Quickset infusion
set (MiniMed) was used because there
was no need for additional adhesive. The
usual antihistamine oral treatment (ceti-
rizine) was maintained.
Since the beginning of constant lispro
infusion, we have not observed any local
reaction at the insertion site of the cathe-
ter or elsewhere. The patient’s glycemic
profile improved significantly. HbA1c,
which was initially at 13.5%, was reduced
to 8.2% after 3 months and remained be-
tween 7.5 and 8% during follow-up. The
average capillary blood glucose values
over the last month were 5.66  1.65
mmol/l premeal and 8.25  1.10 mmol/l
2-h postmeal. She reported less than two
minor hypoglycemic episodes every
week, and two severe episodes occurred
because of physical activity. A hypergly-
cemic episode without ketosis that fol-
lowed transient corticosteroid therapy to
treat an allergic reaction to a wasp sting
was successfully treated with tempo-
rarily increased basal rates (3.5 units/h) of
insulin.
Although our patient developed an
allergy to the insulin molecule itself, she
was successfully treated using continuous
subcutaneous infusion of lispro insulin
with only an external insulin pump. One
year later, although intradermal tests re-
mained positive, particularly with rapid-
acting insulin analogs, we could stop
antihistamine treatment and introduce
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E xtracts of licorice root are widelyused in many countries as flavoringagents, breath fresheners, and
candy. Licorice consumption had been
reported to decrease serum testosterone
concentrations (1). An explanation for
this result was that glycyrrhizic acid, the
active component of licorice, interfered
with 17-hydroxysteroid dehydroge-
nase, which catalyzes the conversion of
androstenedione to testosterone. We
were very interested in the effects of gly-
cyrrhizic acid to decrease serum testoster-
one concentrations. Glycyrrhizin, which
is extracted from the roots of the plant
Glycyrrhiza glabra (licorice), is widely
used for the treatment of chronic hepatitis
in Japan and reportedly reduces the pro-
gression of liver disease to hepatocellular
carcinoma. The efficacy of glycyrrhizin
treatment is currently under investigation
in Europe (2). There are few data available
on the effects of glycyrrhizin on serum
testosterone concentrations (3). We have
recently reported that reduced serum tes-
tosterone concentrations could cause in-
sulin resistance (4) and atherosclerosis (5)
in male patients with type 2 diabetes.
Therefore, we attempted to determine the
effects of glycyrrhizin on serum testoster-
one concentrations in male patients with
type 2 diabetes and chronic hepatitis.
This study included 18 male patients
with type 2 diabetes and chronic hepatitis
who were given weekly glycyrrhizin,
which contained 240–525 mg glycyrrhi-
zic acid, for 1 year and 21 male patients
not given glycyrrhizin. We measured se-
rum concentrations of total and free tes-
tosterone (normal range 2.7–10.7 ng/ml
and 14–40 pg/ml, respectively) and per-
formed carotid ultrasonography (5),
which is used increasingly in clinical re-
search concerning pathophysiology of
atherosclerosis, in those patients.
Clinical characteristics of patients
treated with (n  18) and without (n 
21) glycyrrhizin are as follows: mean age
(66.9  7.1 vs. 66.8  6.7 years), dura-
tion of diabetes (13.7  7.3 vs. 12.6 
10.3 years), BMI (23.0  2.3 vs. 22.7 
1.8 kg/m2), levels of HbA1c (7.4  1.5 vs.
7.0  0.9%), presence of hypertension
(77.8 vs. 66.7%), presence of hyperlipid-
emia (33.4 vs. 38.1%), and history of cig-
arette smoking (61.1 vs. 57.1%) were not
significantly different between groups.
Serum concentrations of total and free
testosterone were significantly lower in
patients given glycyrrhizin than those in
patients not given glycyrrhizin (4.3  2.2
vs. 5.9  1.7 ng/ml, P  0.0113; 6.7 
3.8 vs. 11.1  3.8 pg/ml, P  0.0009,
respectively). Mean intima-media thick-
ness and plaque score by carotid ultra-
sonography were significantly greater in
patients given glycyrrhizin than in pa-
tients not given glycyrrhizin (1.12  0.29
vs. 0.89  0.23 mm, P  0.0385; 6.8 
3.1 vs. 3.7  3.3, P  0.0326, respective-
ly). Glycyrrhizin treatment was an inde-
pendent risk factor (  0.464, P 
0.0433) for atherosclerosis (plaque score)
after adjustment for age, hypertension,
hyperlipidemia, smoking history, and
glycemic control (HbA1c).
Despite a major limitation of small
sample size, this study suggests that gly-
cyrrhizin decreased serum testosterone
concentrations in male patients with type
2 diabetes and chronic hepatitis. Reduced
serum testosterone concentrations may
cause insulin resistance and atherosclero-
sis, as well as sexual dysfunction and de-
creased libido in men. Special attention
should be directed at serum testosterone
concentrations in male patients with type
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Is there a light at the end of the
tunnel?
Pharmacogenetics is the study of ge-netic influence on response todrugs. This is an area of increasing
attention due to the possibilities of im-
proving overall treatment effects in pa-
tients through individual strategies.
Mogensen (1) addresses this subject and
diabetic renal disease in relation to our
study. In the study in question (2), we
masked and prospectively investigated
the renoprotective effects of angiotensin II
receptor blockade (ARB) in hypertensive
type 1 diabetic patients with diabetic ne-
phropathy homozygous for the insertion
(I) or deletion (D) allele of the ACE/ID
polymorphism during 36 months of fol-
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low-up (2,3). We demonstrated that ARB
by losartan confers similar beneficial
renoprotective effects in patients with II
and DD genotypes (2,3). Mogensen
points out a contradiction between our
present study (2) and our previous obser-
vational follow-up study of the influence
of the ACE/ID polymorphism on the long-
term efficacy of ACE inhibition in type 1
diabetic patients with diabetic nephropa-
thy (4). The previous observational fol-
low-up study demonstrated that DD
patients have an accelerated rate of de-
cline of the glomerular filtration rate dur-
ing 7 years of ACE inhibition compared
with patients with the I allele (4). We
want to point out that the studies were
carried out using two distinctly different
types of drugs for blockade of the renin-
angiotensin-aldosterone system, thus the
results should not be expected to be iden-
tical. The present study using ARB was
designed in an attempt to overcome the
impeding interaction between ACE/ID
genotypes and ACE inhibition by block-
ing the renin-angiotensin-aldosterone
system at the receptor site (2,3). There-
fore, demonstration of equal renoprotec-
tion in patients with DD or II ACE
genotypes during ARB treatment is in-
deed distinct from our first study of ACE
inhibition (4) and provides new and im-
portant information by identifying ho-
mozygous DD patients as a group that
may receive specific benefits from ARB
treatment. In addition, our present study
is the first prospective pharmacogenetic
study in diabetic nephropathy (2). The
results indicate that there is a new light
ahead in the treatment of diabetic ne-
phropathy, but further pharmacogenetic
studies should be carried out to identify
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Cirrhosis in Type 1
Diabetes
The possible role of eosinophilia
T ype 1 diabetes is often associatedwith other autoimmune diseases(1), including primary biliary cir-
rhosis (2). Furthermore, type 1 diabetes
and primary biliary cirrhosis may share
similar pathogenetic pathways (3). In
type 1 diabetic patients, the identification
of markers for associated autoimmune
diseases may permit earlier diagnosis and
more effective treatment.
A 46-year-old man with type 1 diabe-
tes (age of onset 26 years) was admitted
into our hospital due to poor glycemic
control (HbA1c 11.3%) with severe daily
hypoglycemia and significant hyperglyce-
mic spikes. At admission, routine blood
tests showed mild eosinophilia (6.7%,
482.4/mmc versus normal 1– 4%, 72–
282/mmc) and markedly elevated values
for -glutamyl transpeptidase (GT) (203
units/l versus normal, 8–61) and alkaline
phosphatase (571 units/l versus normal,
91–258). Aspartate, alanine aminotrans-
ferase, and bilirubin values were normal.
Alkaline phosphatase gradually increased
during hospitalization (from 571 to 683
units/l), whereas GT did not change sig-
nificantly. Mild eosinophilia (5.9%,
403.9/mmc) occurred 18 months be-
fore hospitalization, but all common
causes of eosinophilia were excluded.
Twelve months before hospitalization,
GT and alkaline phosphatase values
were normal. The patient did not show
any history of jaundice, pruritus, or dys-
pepsia. During hospitalization, any
causes of hepatobiliary disease, including
viral infections, were accurately excluded.
Moreover, common causes of eosino-
philia were also excluded. Screening for
autoimmunity showed normal values for
the common panel of autoantibodies (anti-
nuclear, anti–thyroid peroxidase, anti-
thyroglobulin, and anti-cardiolipin) except
for anti-mitochondrial antibodies (titer
1:40).
Abdominal ultrasonography did not
reveal any abnormal findings. Extrahe-
patic biliary tracts were not dilated. Ultra-
sound-guided liver biopsy was then
performed. Histological findings showed
flogistic infiltration of the portal tract and
hepatic lobules. Moreover, there was por-
tal tract fibrosis with focal infiltration of
lobules, including a picture of intrahe-
patic biliary duct disease. This picture was
consistent with stage 2 primary biliary cir-
rhosis according to Scheuer classification
(4). Ursodesoxicholic acid treatment was
begun, and since then cholestasis values
have decreased and glycemic control has
improved.
The present case shows an association
between type 1 diabetes and asymptom-
atic primary biliary cirrhosis. One year
before hospitalization, the patient did not
show abnormal markers for cholestasis,
but 18 months beforehand, he did show
mild eosinophilia. In the last decade, evi-
dence for an association between mild eo-
sinophilia and primary biliary cirrhosis
has constantly increased. Moreover, ac-
cording to most recent studies, mild eo-
sinophilia seems to be an indicator of
early disease stages and is considered a
strong predictor of good response to ur-
sodesoxicholic acid treatment and of bet-
ter prognostic outcomes (5).
To the best of our knowledge, this is
the first case of mild eosinophilia associ-
ated with primary biliary cirrhosis in type
1 diabetic patients. This case suggests that
in type 1 diabetic patients, isolated mild
eosinophilia should be carefully regarded
when common causes of eosinophilia
have been excluded. Indeed, when con-
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sidering the possible association between
type 1 diabetes and primary biliary cir-
rhosis (1–3) in type 1 diabetic patients
with unexplained eosinophilia, GT, al-
kaline phosphatase, and anti-mitochon-
drial antibodies should be evaluated to
discern which subjects are at risk for pri-
mary biliary cirrhosis. In patients with
positive anti-mitochondrial antibodies
but normal GT and alkaline phospha-
tase values, the latter should be strictly
monitored. Patients with anti-mitochon-
drial antibodies and elevated GT and al-
kaline phosphatase values should
undergo a liver biopsy. In this way, mild
eosinophilia may be considered a marker
of asymptomatic primary biliary cirrhosis
at earlier stages, when biochemical and
clinical responses to ursodesoxicholic
acid treatment can lead to better results.
In addition, an early and effective treat-
ment of primary biliary cirrhosis may per-
mit better diabetes control.
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Adiponectin is expressed in and se-creted from visceral fat, and itsplasma level has been reported to
correlate with insulin resistance and tri-
glyceride metabolism in nondiabetic sub-
jects (1,2). However, these relationships
have not been evaluated in Japanese met-
abolically obese normal-weight (BMI
25 kg/m2 and visceral fat areas [evalu-
ated by abdominal CT scanning] 100
cm2) men with normal glucose tolerance
(NGT) (3–5).
The present study comprised 16 met-
abolically obese normal-weight men
(aged 35.6  1.8 [mean  SE] years, BMI
23.8  0.3 kg/m2, visceral fat areas
130.8  5.2 cm2) and 15 age-matched
normal men (BMI 25 and visceral fat
areas 100 cm2) (aged 33.6  1.8 years,
BMI 20.9  0.3 kg/m2, visceral fat areas
56.5  5.1 cm2) with NGT.
The plasma levels of adiponectin were
measured using a radioimmunoassay kit
(Linco Research, St. Charles, MO).
Comparisons between metabolically
obese normal-weight and normal subjects
were done using the Mann-Whitney U
test, and correlations were evaluated by
Spearman’s rank correlation.
There were no significant differences
in plasma levels of adiponectin between
metabolically obese normal-weight
(10.2  1.3 ng/ml) and normal subjects
(12.0  0.8 ng/ml). The BMI (P  0.01)
and serum levels of triglyceride (1.67 
0.14 vs. 0.92  0.09 mmol/l, P  0.01)
were significantly increased in metaboli-
cally obese normal-weight subjects com-
pared with normal subjects. The glucose
infusion rate (index of insulin resistance
during the euglycemic-hyperinsulinemic
clamp study) in metabolically obese nor-
mal-weight subjects (53.9  3.4 mol 
kg	1  min	1; P  0.01) were signifi-
cantly decreased compared with normal
subjects (65.8  2.7 mol  kg	1  min	1)
(4,6).
The plasma levels of adiponectin were
significantly correlated with glucose infu-
sion rate (r  0.509, P  0.05), serum
levels of triglyceride (r  	0.730, P 
0.01), and the visceral fat areas (r 
	0.597, P  0.05) in metabolically obese
normal-weight subjects.
There were not significant correla-
tions between plasma levels of adiponec-
tin and glucose infusion rate (r  0.146,
P  0.584), serum levels of triglyceride
(r  	0.446, P  0.095), or visceral fat
areas (r  	0.214, P  0.423) in normal
subjects.
Visceral fat is an important determi-
nant factor of the plasma level of adi-
ponectin, which is known to exert an
insulin-sensitizing effect (2,7). Unexpect-
edly, similar plasma levels of adiponectin
and different glucose infusion rates were
observed in metabolically obese normal-
weight and normal subjects. The small
number of patients may be the explana-
tion for this unexpected result. Further
study should be carried out in a larger
population of Japanese metabolically
obese normal-weight subjects.
Significant correlation between
plasma levels of adiponectin and glucose
infusion rate was observed in metaboli-
cally obese normal-weight subjects.
Plasma adiponectin levels may play an
important role in the development of in-
sulin resistance in Japanese metabolically
obese normal-weight subjects.
The plasma levels of adiponectin were
significantly correlated with the serum
levels of triglyceride in metabolically
obese normal-weight subjects. Cnop et al.
(2) demonstrated that association of adi-
ponectin with increased visceral fat may
shift the fate of apolipoprotein B away
from degradation toward secretion from
the liver, resulting in elevated triglyceride
concentrations. This phenomenon might
have occurred in our Japanese metaboli-
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M icroalbuminuria, a predictor forovert nephropathy and early car-diovascular mortality, is always
associated with hypertension, hypergly-
cemia, and dyslipidemia (1). In the study
of Tai et al. (2), performed in Taiwanese
type 2 diabetic patients, albumin excre-
tion rate was significantly associated with
hypertension but not with glycemic con-
trol. To further examine the association
between lipid profile and microalbumin-
uria in Taiwanese type 2 diabetic subjects,
a total of 260 nonsmoking patients (117
men, 143 women; mean age  SD,
60.7  11.0 years) with normal renal
function and not using antihypertensive
or lipid-lowering agents were cross-
sectionally recruited. Normoalbuminuria
(n  152) and microalbuminuria (n 
108) were defined as urinary albumin-to-
creatinine ratios (ACRs) 30 and 30–
299 g /mg , r e spec t i ve l y . L ip id
parameters included serum total choles-
terol, triglycerides, HDL and LDL choles-
t e ro l , apo l ipopro te in A1 , and
apolipoprotein B (ApoB). Potential con-
founders (age, sex, BMI, duration of dia-
betes, insulin therapy, systolic and
diastolic blood pressure, and HbA1c) were
adjusted for in multivariate analyses.
Mann-Whitney U test, Spearman correla-
tion coefficients, and logistic regression
were used.
The results showed that among the
lipid profile, only total cholesterol and
ApoB were significantly (P  0.05) differ-
ent between patients with microalbumin-
uria and those with normoalbuminuria
(208.5  40.9 vs. 197.5  38.6 mg/dl for
total cholesterol and 123.1  37.9 vs.
106.4  29.0 mg/dl for ApoB). For cor-
relation coefficients, only ApoB was sig-
nificantly correlated with ACR ( 
0.166); total cholesterol showed border-
line significance (  0.113, 0.05  P 
0.1). Multivariate-adjusted odds ratios
(ORs) (95% CI) for microalbuminuria
were significant only for ApoB (1.016
[1.007–1.024]) and total cholesterol
(1.007 [1.000–1.014]), but total choles-
terol was nonsignificant with additional
adjustment for ApoB. While the lipid pa-
rameters were treated as binary variables
with cut points at medians and using the
lower halves as reference groups, only
ApoB (cut point: 108 mg/dl) showed sig-
nificant multivariate-adjusted OR for mi-
croalbuminuria (2.209 [1.303–3.746]).
Atherogenic lipoproteins can infil-
trate into the glomerular endothelium
and mesangial cells, initiating a cascade of
events similar to atherosclerosis (3). Sam-
uelsson et al. (4) reported that ApoB was
associated with a declining glomerular fil-
tration rate in patients with chronic renal
disease and that renal dyslipidemia was
predominantly associated with the accu-
mulation of ApoB-containing lipopro-
teins in both sclerotic and nonsclerotic
glomeruli (5). The observation of the
present study in Taiwanese type 2 diabetic
patients suggests that ApoB-containing
lipoproteins could also initiate early glo-
merular injury leading to incipient dia-
betic nephropathy with microalbuminuria.
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risk factors for atherosclerosis
M icroalbuminuria is a wel l -established risk factor for athero-sclerosis in patients with type 2
diabetes (1,2). In this cross-sectional
study, we examined the effect of mi-
croalbuminuria on the intima-media
thickness (IMT) of the carotid arteries, an
index of early atherosclerosis (3), in pa-
tients with type 2 diabetes.
We studied a total of 120 subjects
with type 2 diabetes (60 men and 60
women, aged 61.4  6.8 years, duration
of diabetes 10.4  7.7 years, and HbA1c
7.9  1.7% [mean  SD]) randomly se-
lected from the outpatient diabetes clinic.
Microalbuminuria was diagnosed when
albumin excretion (measured by radioim-
munoassay) was 20 and 200 g/ml in
two of three overnight, timed urine col-
lections. Subjects were divided into two
groups based on the presence of mi-
croalbuminuria.
All carotid B-mode real-time ultra-
sound measurements were performed by
the same experienced physician, who was
blinded to the patient’s urine albumin sta-
tus. Measurements of the IMT were per-
formed in both the right and left common
carotid arteries (CCAs) and internal ca-
rotid arteries (ICAs), as previously de-
scribed (4).
Forty-six (38.3%) subjects had mi-
croalbuminuria. There were no signifi-
cant differences between the study groups
in terms of sex, age, blood pressure, BMI,
waist-to-hip ratio, duration of diabetes,
HbA1c, type of antidiabetic treatment,
smoking habit, fasting plasma glucose, in-
sulin, triglycerides or HDL cholesterol,
and the use of statins and ACE inhibitors.
Plasma total and LDL cholesterol levels
were higher in the microalbuminuric
group (P  0.02). The IMT/CCA values
were higher in the microalbuminuric
group compared with the normoalbu-
minuric group (0.99  0.14 vs. 0.89 
0.15 mm, respectively; P  0.001), but
this was not the case concerning the IMT/
ICA values (0.94  0.14 vs. 0.93  0.16
mm, respectively; P  0.69).
Multivariate analysis, after adjust-
ment for a number of confounding fac-
tors, such as age, sex, blood pressure,
BMI, waist-to-hip ratio, duration of dia-
betes, HbA1c, type of antidiabetic treat-
ment, smoking status, plasma lipids, and
the use of ACE inhibitors and statins,
demonstrated that only the presence and
degree of microalbuminuria were inde-
pendently associated with IMT/CCA (B 
0.01, SE[B]  0.003, P  0.0001 and B 
0.0001, SE[B]  0.00001, P  0.02, re-
spectively). In addition, it is noteworthy
that microalbuminuric patients treated
with ACE inhibitors tended to have lower
IMT/CCA values than patients not treated
with this class of medication (P  0.06),
whereas no such difference was found
with the use of statins. The lack of associ-
ation between microalbuminuria and the
IMT/ICA value is explained by the fact
that ICAs at the bifurcation are more sen-
sitive to local atherosclerosis and do not
necessarily reflect the status of the arterial
tree. In nondiabetic subjects, the IMT/
CCA shows a graded association with var-
ious cardiovascular risk factors and thus
can be used as an indicator for the presence
of atherosclerosis in other arteries (3).
It is concluded that microalbumin-
uric subjects with type 2 diabetes have
higher IMT/CCA values than normoalbu-
minuric subjects and that the presence as
well as the degree of microalbuminuria
are independent predictors of IMT/CCA.
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Response to Amin et al.
W e read with great interest the re-cent article by Amin et al. (1),reporting that differences in
IGF-1 and androgen concentrations and
disruption of glycemic control accom-
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pany development of microalbuminuria
at puberty. A possible association of dia-
betic microvascular complications with
hormonal abnormalities related to this
developmental period is important be-
cause risk of microvascular complications
increases at puberty, especially in female
subjects.
The effect of testosterone on insulin
resistance is opposite between men and
women; low testosterone concentrations
in men (2) but high testosterone concen-
trations in women (3) favor insulin resis-
tance. Accordingly, the authors might
have chosen to evaluate the effect of tes-
tosterone for each sex, presenting testos-
terone and sex hormone– binding
globulin (SHBG) concentrations and the
free androgen index (FAI) (FAI  testos-
terone 
 100/SHBG) according to sex in
Table 2. We also consider the effects of
other sex hormones such as estrogen and
progesterone on the development of mi-
croalbuminuria to be important questions.
Low testosterone concentrations promote
insulin resistance and atherosclerosis in ag-
ing men (2,4). However, low testosterone
concentrations may be such a rarity that
they have little effect on the development of
microalbuminuria in male subjects with
type 1 diabetes at puberty.
The authors showed testosterone
concentrations and FAI to be higher in
female subjects with microalbuminuria.
The age-specific normal range and the
proportion of subjects with testosterone
concentrations and FAI beyond upper
normal limits would be important to know
because these patients would be especially
prone to insulin resistance. Insulin resis-
tance secondary to hyperandrogenism
might play a role in the development of
microalbuminuria during puberty in fe-
male subjects with type 1 diabetes, and
these patients should be carefully investi-
gated for early signs of macrovascular and
microvascular complications. The au-
thors found that free IGF-1 and testoster-
one concentrations did not differ between
male subjects with and without mi-
croalbuminuria, stating that when sexes
were considered separately, microalbu-
minuria was significantly associated with
poor glycemic control only among male
subjects. Thus, the report’s title should
have stressed low IGF-1 and high tes-
tosterone in female subjects with type 1
diabetes at puberty who develop micro-
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Response to Shiloah et al.
The article by Shiloah et al. (1) in noway answers the question of wheth-er the glucose dysregulation ob-
served in patients with acute psychotic
episodes is due to the stress of the psycho-
sis. The design of this study has major
flaws that make it impossible to draw any
firm conclusions from the findings pre-
sented. First, the term “acute psychotic
stress” is not defined by the authors and is
certainly not found in the DSM-4 hand-
book as indicated by the authors. Further-
more, no diagnostic criteria are used to
confirm the diagnoses of “chronic schizo-
phrenia” or indeed “residual or paranoid
schizophrenia.” Though we are told that
patients with “acute psychotic stress”
were hospitalized, we are also told on page
1463 that “All patients were well con-
trolled before admission.” Exactly what
this statement means is not explained.
Patients taking medications that
could influence insulin or glucose activity
were excluded. Yet we are given a list of
medications in “Patients and study de-
sign” in the second point prefaced by
“i.e.,” implying that the list given is com-
plete. Yet what of other atypical and typ-
ical agents that have been alleged to
induce glucose dysregulation? Leaving
aside the issue of medication, no severity
of illness or indeed abnormal movement
scales are given, so we have no idea as to
how sick these patients actually are. In-
stead we are told that a “subjective impres-
sion” of their “stress” was documented
using a seven-point clinical global impres-
sion (CGI). The authors state that it is “sim-
ilar to the Global Assessment Scale,” but
there are no references provided that indi-
cate it has been adequately validated. In
contrast, in a recent study using DSM-4 cri-
teria and well-validated scales (Brief Psy-
chiatric Rating Scale and Schedule for the
Assessment of Negative Symptoms & Ab-
normal Involuntary Movement Scale), we
found no association between severity of
illness or abnormal movements related to
fasting insulin, glucose, or insulin resis-
tance (2), indicating the acute presenta-
tion was not responsible for the glucose
dysregulation observed in first episode,
drug-naı̈ve patients with schizophrenia.
In Table 1 we are told that that their
mean  SD age was 39  10.5 years but
the age range was 19–37 years. How can
the average age be higher than the maxi-
mum age range given? The range of the
BMI was from 16.0 to 40.1 kg/m2, which
means that some patients were potentially
anorexic and others were morbidly obese.
Was it really appropriate to measure such
metabolic parameters in patients with
such vastly differing BMIs? Lastly, in Ta-
ble 1 we are told that patients had a host of
cardiovascular risk factors and diseases. Is
it not likely that the insulin insensitivity
and abnormal -cell function was present
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many years before the time of admission
as some of the “background diseases” are
consequent upon having problems with
glucose regulation?
Table 2 clearly shows that patients
were most insulin sensitive on admission
and following discharge, least sensitive
with corresponding changes in -cell
function, and that fasting plasma glucose
levels did not vary throughout the study,
which would indicate that treatment with
typical antipsychotic medication may
have contributed to their findings. How-
ever, if on admission, patients were di-
vided into “low and high” categories
according to their CGI scores, significant
differences began to emerge. The “low
and high” scores were either 6 or 6
(the maximum being 7), respectively.
Therefore, the authors compared the
most extremely ill with all of the other
patients. The cutoff figures were picked
arbitrarily with no scientific reasons given
for doing so. Furthermore, we were not
told how many patients fit into each cat-
egory. From a statistical perspective, the
correlation coefficient for CGI and insulin
was r  0.37 and for CGI and fasting
blood glucose was 0.47; the respective r2
values are 0.22 and 0.14, implying that
71% of the variance cannot be explained
by these findings. Namely, that “acute
psychotic stress” was not primarily re-
sponsible for their results. Indeed, we are
told later in the RESULTS section that there
was a negative correlation between insu-
lin sensitivity and “psychotic stress” on
admission, but we are not given any r
value or indeed any indication of the
numbers of patients in each group, mak-
ing it impossible to judge what real signif-
icance these findings have.
The authors state in the CONCLUSIONS
that prestudy medications cannot explain
their findings because atypical antipsy-
chotics were not used. However, typical
antipsychotics have been implicated in
the abnormal glucose regulation seen in
schizophrenia, as the authors themselves
state. In addition, we are not told how
long patients were free of their medica-
tions before admission, as certain intra-
muscular preparations can have effects
for many months after their last adminis-
tration. Finally, the importance of chronic
stress as a potential pathogenetic mecha-
nism in the development of type 2 diabe-
tes in schizophrenia is evident; however,
the results presented by Shiloah et al. (1)
do not provide any evidence for acute
stress causing such glucose dysregulation.
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The Effect of Weight
Loss on Endothelial
Functions in Obesity
Response to Sciacqua et al.
W e read with interest the article bySciacqua et al. (1) showing im-provement of endothelial func-
tion in healthy obese subjects (no sex
specified) after short-term (12–16 weeks)
weight loss. By adopting a low-calorie diet
associated with exercise, only two-thirds
of the subjects enrolled in the study were
able to achieve a reduction of at least 10%
of initial weight (due to a high drop-out
rate). In these subjects, maximal vasodi-
lator response to the highest dose of ace-
tylcholine increased from 211 to 358% of
baseline, indicating improved endotheli-
um-dependent vasodilation. The choice
of obese subjects without known addi-
tional risk factors was the right one to
make, thus avoiding the many possible
confounders affecting endothelial function.
However, we disagree with the con-
clusions of the authors that “this is the
first study to prospectively evaluate the
effects of weight loss and physical activity
on endothelium-dependent vasodilation
of obese normotensive subjects,” as our
study of a multidisciplinary program, in-
cluding low-calorie Mediterranean-type
diet, exercise, and behavioral and nutri-
tional counseling in obese women, was
published earlier (2). In that study, we
performed the first long-term prospective
evaluation of the effect of weight loss on
endothelial functions and circulating
markers of vascular inflammation in 56
obese but otherwise healthy women (2).
After 12 months, the women lost at least
10% of their initial weight (	9.8  1.5 kg
[range 7.5–13]) and increased their phys-
ical activity from 46  12 to 131  29
min/week. All of this was associated with
improved endothelial functions as assessed
by the hemodynamic (blood pressure de-
crease) and rheologic (platelet aggregation
response to ADP) responses to L-arginine (3
g i.v.), the natural precursor of nitric oxide
(3). Moreover, the raised circulating con-
centrations of proinflammatory cytokines
(interleukin-6 and tumor necrosis factor-)
and intracellular and vascular cell adhesion
molecules (ICAM-1 and VCAM-1, respec-
tively) that the obese women had at baseline
were significantly reduced after weight loss.
The pathogenesis of endothelial dys-
function in obesity remains uncertain; the
relative roles of insulin resistance, circu-
lating nonesterified fatty acids, or adipo-
cyte-associated cytokines are being
delineated. For example, both nonesteri-
fied fatty acids (4) and interleukin-6 or
tumor necrosis factor- (5) can induce
vascular dysfunction and insulin resis-
tance. In obese individuals, circulating
nonesterified fatty acids and proinflam-
matory cytokines are increased, which
may explain, at least in part, their in-
creased cardiovascular risk. We have also
shown that a long-term (2 years) multi-
disciplinary program aimed to reduce
body weight through lifestyle changes in
obese women was associated with reduc-
tion of insulin resistance and increased
adiponectin concentrations (6). Because
adiponectin possesses anti-inflammatory
properties and improves glucose toler-
ance (7), hypoadiponectinemia may con-
tribute to the low-grade inflammation
and the insulin resistance that character-
ize human obesity. Thus, the increased
cardiovascular risk of obese people may
be seen as the result, at least in part, of
increased inflammatory stimuli and de-
creased anti-inflammatory mechanisms.
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Modem Transmission
of Glucose Values
Reduces the Costs of
and Need for Clinic
Visits
Response to Chase et al.
W e found the article by Chase et al.(1) very interesting. Obviously,other authors share our worries
concerning fewer clinic visits and less
costs for diabetic patients because they
are dramatically increasing in number.
We presented (2) and published (3) a
study on the same subject but used a
somewhat different technique for trans-
mitting glycemic values from the patient
to the diabetologist. Our patients sent
their encrypted data via e-mail. The gly-
cemic controls were performed with a
Onetouch Profile meter connected to In-
touch software (Lifescan) on a personal
computer. This system seems more flexi-
ble than the Acculink modem because the
patients could provide comments with
their data. The same method was used for
a reaction in which the diabetologist was
able to immediately respond when he re-
ceived the results. In our study, the initial
and final HbA1c values were not different.
The actual meters do not allow for easy
introduction of insulin dosages, and this
important information should be sent by
the patients so that they can receive advice
regarding treatment. We think this is a
drawback in our methods. In conclusion,
modem transmission of blood glucose
values help diabetic patients maintain
good glycemic control at fair cost, but it
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Reduces the Costs of
and Need for Clinic
Visits
Response to Perlemuter and
Yomtov
W e thank Perlemuter and Yomtov(1) for their comments in thisissue of Diabetes Care regarding
our article (2). It seems that their previous
study (3) and our study show similar re-
sults. They did not provide the ages of
their participants, but “nine men and one
woman” are mentioned, and our suspi-
cion is that these subjects were a bit older
than those in our population. It was also
not stated if the subjects had type 1 or
type 2 diabetes, though the latter seems
likely. As our study dealt specifically with
people 15–20 years of age with type 1
diabetes, it is likely that the two experi-
ences are complementary. The main dif-
ference between our studies is in the
response method, e-mail versus tele-
phone. There are advantages to both
methods. E-mail saves time when com-
pared with the necessary repeat phone
calls when people are not at home. The
telephone allows person-to-person con-
tact in which questions and answers can
be used to reach a conclusion. It is also
not as limited in dealing with the draw-
back mentioned by Perlemuter and Yom-
tov, that of dealing with emergencies.
Currently, our clinic staff very effectively
handles 20–30 calls per day related to ke-
tones (4) or hypoglycemia. Subjects cur-
rently using e-mail switch to telephone
calls for emergencies. A major goal of our
study was to determine if e-mail commu-
nication could reduce the need for clinic
visits for some subjects, and this was
shown to be the case. We certainly agree
that the electronic transmission of medi-
cal data is feasible and beneficial.
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